In this report, the United States Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 in these regions, from 2013 to 2025 (forecast).

United States Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market competition by top manufacturers/players, with Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
Paion AG
Pfizer Inc
Primex Pharmaceuticals Oy
Shire Plc
...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
EL-001
LASSBio-785
LASSBio-786
Midazolam Hydrochloride
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
General Anesthetic Effect
Insomnia
Hypertension
Others